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Abstract
Regeneration of skeletal muscle after injury is limited by scar formation, slow healing time
and a high recurrence rate. A therapy based on platelet-rich plasma (PRP) has become a
promising lead for tendon and ligament injuries in recent years, however concerns have
been raised that PRP-derived TGF-β could contribute to fibrotic remodelling in skeletal mus-
cle after injury. Due to the lack of scientific grounds for a PRP -based muscle regeneration
therapy, we have designed a study using human myogenic progenitors and evaluated the
potential of PRP alone and in combination with decorin (a TGF-β inhibitor), to alter myoblast
proliferation, metabolic activity, cytokine profile and expression of myogenic regulatory fac-
tors (MRFs). Advanced imaging multicolor single-cell analysis enabled us to create a valu-
able picture on the ratio of quiescent, activated and terminally committed myoblasts in
treated versus control cell populations. Finally high-resolution confocal microscopy validat-
ed the potential of PRP and decorin to stimulate the formation of polynucleated myotubules.
PRP was shown to down-regulate fibrotic cytokines, increase cell viability and proliferation,
enhance the expression of MRFs, and contribute to a significant myogenic shift during dif-
ferentiation. When combined with decorin further synergistc effects were identified. These
results suggest that PRP could not only prevent fibrosis but could also stimulate muscle
commitment, especially when combined with a TGF-β inhibitor.
Introduction
Musculoskeletal injuries that result in the necrosis of muscle fibres are frequently encountered
in clinical and sports medicine [1,2]. Despite their clinical significance, current therapeutic
options remain rather conservative and include the R.I.C.E. (rest, ice, compression, elevation)
principle or the controversial therapy using corticosteroids as well as non-steroidal anti-
inflammatory drugs [3].
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Injured skeletal muscle has regenerative capacities and can repair spontaneously; however,
this process is often incomplete because of overgrowth of the extracellular matrix and the depo-
sition of collagen, which leads to significant fibrous scarring [4,5,6]. Fibrotic remodelling fur-
ther limits the functionality of the muscle and represents a significant risk factor for the injury
to recur.
Platelet-rich plasma (PRP), an autologous platelet concentrate, has gained popularity for
the therapy of tendon and ligament injuries [7] despite few and limited relevant scientific re-
ports about its equivalent therapeutic efficiency. PRP is isolated by the centrifugation of whole
blood, obtained from an individual, allowing extraction of thrombocytes rich in granules con-
taining various growth factors [8]. As such, the patient-derived endogenous preparation is the-
oretically perfect to be administered locally at the site of the tissue injury. Several individual
PRP-derived growth factors have positive regenerative effects in muscle healing [9,10,11,12];
nonetheless, PRP-derived TGF-β could potentially stimulate fibrosis as shown previously
[1,13]. Because of its presence in PRP, its application into skeletal muscle raises concerns due
to the risk of even greater fibrotic remodelling of the tissue [14].
Fibrotic effects of TGF-β are balanced by decorin, a component of the extracellular matrix
of all collagen-containing tissues [15]. It has been shown that decorin inhibits both TGF-β as
well as myostatin (MSTN), which is another, skeletal muscle-specific, member of the TGF-β
superfamily [16,17,18,19,20]. Both cytokines up-regulate the expression of each other [19] and
inhibit the activation of satellite cells [14,21,22], myoblast proliferation [19,23] as well as their
myogenic differentiation [13,24,25]. Alternatively they promote fibroblast commitment
[1,5,19] (Fig. 1). We hypothesise that by the simultaneous use of the anitfibrotic agent decorin
with PRP we might reduce TGF-β-dependent fibrotic scaring while at the same time stimulat-
ing muscle regeneration via the introduction of homologous growth factors.
Figure 1. Schematic representation of muscle regeneration on the regulatory level. During skeletal muscle regeneration various MRFs are being
expressed (in blue). Satellite cells differentiate into myoblasts which proliferate and either further differentiate into polynucleated myotubules or transform into
myofibroblasts. TGF-β and MSTN play an important role in inhibiting/stimulating these steps (marked with +/- symbols).
doi:10.1371/journal.pone.0117302.g001
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A typical feature during muscle differentiation are transient changes in the expression levels
of various muscle specific transcription factors [26] (Fig. 1). Myogenic regulatory factors
(MRFs) such as Pax3/7, Myf5, MyoD, myogenin and Mrf4 are expressed exclusively in skeletal
muscle [27] and govern the expression of multiple genes during myogenesis [28,29]. MyoD is
required for the determination of skeletal myoblasts whereas myogenin acts later in the pro-
gram, likely as a terminal differentiation factor [27]. Although it has been shown that decorin
alters the expression of MRFs in skeletal muscle after injury, such a mode of action has not yet
been studied with PRP. Furthermore, despite the results from two recent studies showing posi-
tive effects of PRP on skeletal muscle proliferation, no data about TGF-β and MSTN expression
has been provided [30,31].
In our study we used a human CD56 positive myoblast cell line and evaluated the potential
of PRP alone and in combination with decorin, a TGF-β inhibitor to alter myoblast prolifera-
tion, metabolic activity, TGF-β and myostatin activation and expression of myogenic regulato-
ry factors (MRFs). Imaging flow cytometry enabled us to create a valuable and unique insight
into the ratio of quiescent, activated and terminally committed single myoblasts in treated ver-
sus control cell populations. Finally high-resolution confocal microscopy validated the poten-
tial of PRP and decorin to stimulate the formation of desmin-expressing
polynucleated myotubes.
Materials and Methods
Cell culture isolation and cultivation
We used the human CD56+ positive myoblast cell line (hMC) [32,33] previously characterized
and stored at the Institute of Physiology, University of Maribor. The hMC cell line was main-
tained in DMEM (Life Technologies Ltd, Paisley, UK) including 100 Units/ml of penicillin,
1 mg/ml of streptomycin and 2 mmol of L-glutamine, as well as 20% bovine serum (Life Tech-
nologies Ltd, Paisley, UK) at 37°C in an atmosphere of 5% CO2. The medium was routinely
changed every three days to the point of experimentation. Furthermore, during experiments
DMEM was used without serum to exclude the influence of contained growth factors and to
simulate conditions after injury as previously described by Li et al [30], while PRP and decorin
(R&D Systems, Minneapolis, MN, USA) were added to non-control wells.
Preparation of PRP-derived growth factors
PRP derived from various donors was prepared as previously described by Doucet et al. and
Schallmoser et al. [34,35,36]. All participants provided their written consent to participate in
the study. The consent procedure and the study were approved by the Slovenian national ethics
committee and the institutional review board at the University Medical Centre Maribor. One
hundred ml of blood was collected from five single blood donations. Blood was drawn into a
tube containing 10 mL Acid Citrate Dextrose (ACD-A) anticoagulant. Five mL of PRP was
then prepared using a Magellan Plasma Separator (Medtronic, Minneapolis, USA) according
to the manufacturer's protocol. Furthermore, we froze the PRP units to-80°C¸without further
manipulation. This was followed by thawing of the units in a water bath at 37°C until ice clots
disappeared. We repeated this process 5 times in order to lyse the platelets and release the
growth factors. Mechanical lysis was the method of choice in order to preserve chemically un-
hampered samples. The solution was centrifuged for 10 minutes at 1,500 rpm, and the superna-
tant was used for ultrafiltration (0.22 μm filter size) in order to remove any residual particles as
these tend to aggregate and may induce alloimmunization. One point five mL of suspension
containing growth factors was diluted with DMEM (Sigma-Aldrich, Grand Island, USA) in
order to make 5%, 10% and 20% solutions of PRP-derived growth factors.
PRP and TGF-β Antagonist Induce Myogenesis
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Viability of treated cell cultures
To determine the effect of PRP-derived growth factors and decorin on the viability of hMC we
performed a Tetrazolium [3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide]
(MTT) assay. The cells were seeded at 10,000 cells/well in 96-well plates at 37°C in a humidified
CO2 incubator until they were confluent. DMEM prepared with different concentrations of
PRP exudates (5%, 10%, and 20%) and decorin (10 ng/mL, 25 ng/mL, and 50 ng/mL) were
added to the cells, which were further cultured for 4 hours. MTT 5 mg/mL (Sigma) was used
for the quantitative determination of cell viability as previously described [37,38].
Proliferative ability of exposed cell cultures
To perform the cell proliferation assay, hMCs were separately seeded at 10,000 cells/well in 96-
well plates at a concentration of 30 viable cells per well. DMEM prepared with different con-
centrations of PRP exudates (5%, 10%, and 20%) and decorin (10 ng/mL, 25 ng/mL, and
50 ng/mL) were added and incubated for 7 days at 37°C in an atmosphere of 5% CO2. After
incubation we stained the cells with crystal-violet and measured the absorbance at 595 nm.
Enzyme-Linked Immunosorbent Assay
Cells were seeded at 10,000 cells/well on 96-well plates. After 48 hours of incubation with 10%
and 20% PRP-exudate and decorin (25 μg/mL) the TGF-β and MSTN levels in supernatants
were assayed using commercially available enzyme-linked immunosorbent kits (Invitrogen
Co., Camarillo, USA and USC Life Science Inc., Wuhan, China) following the manufacturer's
protocol. Additionally, we measured the TGF-β concentration in a PRP exudate sample only to
show its presence before applying it to the culture. Triplicates were performed for all assays.
Myogenic differentiation
For myogenic differentiation, myoblasts were seeded in 4-well chamber slides at 10,000 cells/
well and 48-well plates at 5,000 cells/well. After 24 hours PRP-exudate, decorin and their com-
bination was added to DMEM without bovine serum, while no drug was added to the control
group. After immunostaining, the cells were prepared for microscopical examination and
Image Stream single-cell analysis to evaluate the expression of cell surface markers such as
CD56 and the myogenic markers MyoD, Myogenin and desmin as further described below.
Confocal imaging. Immunocytochemical staining was performed as previously described
[39]. Briefly, the cells were seeded in 4-well chamber slides and cultured with a 10% PRP exu-
date, decorin 25 ng/mL and their combination. After 4 days the cells were fixed, permeabilized
and stained with primary and secondary antibodies against desmin (FITC), α-tubulin (goat-
anti rabbit IgG Cy3), and nuclei (DRAQ5), all obtained from Abcam (Cambridge, UK). Tripli-
cates were performed for the analysis. Optical images were acquired at the center of chamber
slides where the cell density is at its highest using a Leica TCS SP5 II confocal microscope
(Leica Microsystems Ltd., Mannheim, Germany) and analyzed using Photoshop CS6 (Adobe,
San Jose, USA), where a “Color Range” tool was used in combination with a histogram palette
to count the pixels that correspond to desmin-positive areas in an image.
Imaging multicolor flow cytometry. In order to quantitatively determine myogenic
differentiation of cultured myoblasts, we analyzed the cells using the imaging flow cytometer
ImageStreamX (Amnis Corporation, Seattle, USA). After harvesting, followed by permeabiliza-
tion, we stained the cells simultaneously with antibodies against CD56 (CD56-APC conjugate;
BD Pharmingen, Heidelberg, Germany), MyoD (goat MyoD and bovine anti-goat IgG PE
conjugate; Santa Cruz GmbH, Heidelberg, Germany) and myogenin (AlexaFluor 488; R&D
PRP and TGF-β Antagonist Induce Myogenesis
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Systems, Abingdon, UK) according to the manufacturer’s protocols. We acquired cell images
of 5,000 events per sample at 40 x magnification using 488 nm and 658 nm lasers and fluores-
cence was collected using three spectral detection channels. For triple-stained cells (CD56,
MyoD and Myogenin), three single-stained controls were used to compensate fluorescence be-
tween channel images. Cell images were analyzed with the IDEAS image-analysis software
(Amnis). First, we gated the aspect ratio versus cell area to isolate a population of single cells
on a bivariate plot. Cells within the focal plane were further selected using a two-dimensional
plot of image contrast versus root-mean-squared (rms) gradient. We scouted for the presence
of MyoD and myogenin exclusively in CD56 positive cells by measuring the intensity of each
probe. Results are expressed as percentage ratios between the cells positive for CD56 only,
those additionally positive for MyoD and those expressing also myogenin or myogenin alone
in each treated and untreated population of cells, respectively.
Statistical analysis
Data collected was analyzed using the Statistical Package for Social Sciences (SPSS) version 16.
All of the results from this study are expressed as the mean +/- S.D. The differences between
means were considered statistically significant if p< 0.05. Comparison between groups was
made by a Student’s t test, two-way ANOVA for multiple comparisons and Bonferroni post-
hoc analysis. A Chi2 test was used to analyze the results from image flow cytometry. SPSS soft-
ware was used for statistical analysis.
Results
PRP enhances viability of hMCs
The mitochondrial activity of cells, as determined by the MTT assay, was significantly in-
creased (p<0.001) after exposure to tested concentrations of PRP exudates. Similarly, viability
was elevated in all tested concentrations of decorin, except 50 ng/ml (Fig. 2). PRP 20% and
10% exudates enhanced the viability of cells to more than 400% when compared to the control
(p<0.001). The viability of cells treated with PRP exudates was also significantly higher when
compared to both decorin concentrations of 25 ng/ml and 50 ng/ml (p<0.001) whereas there
was no significant difference between 10% and 20% PRP exudate concentrations.
Figure 2. MTT assay. Three independent tests were performed and the results were expressed by the mean
ratios (%, ± SD) of absorbance in treated wells to those in control wells. ANOVA, *p<0.001, **p<0.05
compared to control.
doi:10.1371/journal.pone.0117302.g002
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PRP enhances the proliferative ability of hMC
We performed a crystal violet assay to determine the proliferative rate of cells incubated for 7
days with two different decorin and PRP exudate concentrations (Fig. 3). Both decorin concen-
trations did not show a significant effect on cell proliferation compared to the control; however,
cultivation with both PRP exudates leads to a 5-fold increase in cell proliferation (p<0.001)
with no significant differences between them.
PRP and decorin—both and in combination down-regulate TGF-β and
MSTN expression by hMCs
Decorin was shown to down-regulate the expression of TGF-β when compared to the control
by more than 15% (0.552±0.014 vs. 0.676±0.008 p<0.001) but significantly less than both 10%
and 20% PRP exudate concentrations (0.466±0.0.017 and 0.467±0.00027 p<0.005). Tested
PRP exudates significantly down-regulated TGF-β expression by more than 30% (p<0.001)
(Fig. 4). The pure PRP exudate sample is more than 30% (0.913±0.011 vs. 0.676±0.008,
p<0.001) richer in TGF-β concentration than a control sample of cultivated muscle cells con-
firming that PRP represents an exogenous source of TGF-β.
Similarly, the MSTN expression levels were significantly down-regulated by both decorin and
PRP exudates (Fig. 4). MSTN levels of cells treated with decorin were decreased by 28.4%
(p<0.001) and 23.1% by PRP (p<0.001) when compared to the control group. There was no sig-
nificant difference between both PRP exudate concentrations withregard to MSTN expression.
Since no significant differences in cell viability and cytokine expression of 10% and 20%
PRP exudates were found, we performed further experiments with a lower exudate concentra-
tion (10%). When cultivating cells with a combination of decorin 25 ng/ml and 10% PRP exu-
date, the TGF-β cytokine expression was further down-regulated by 59.9% when compared to
the control and twice as much when treated with PRP exudate or decorin alone (Fig. 5). MSTN
levels were decreased by 24% compared to the control but were not significantly lower than in
cells treated with PRP exudate or decorin alone.
PRP and decorin act synergistically towards myogenic differentiation of
hMCs
ImageStream analysis revealed the differences in myogenic differentiation between the control,
PRP and decorin treated groups, as well as their combinations. We captured and analyzed
Figure 3. Myoblast proliferation rate. The figure shows the proliferation of myoblasts after 7 days of incubation with DMEM supplemented with decorin 10
ng/ml, decorin 25 ng/ml, 10% PRP exudate and 20% PRP exudate. Three independent tests were performed and the results are expressed by the absolute
absorbance values (in blue) and mean ratios (%, ± SD) of absorbance in treated wells to those in control wells (in grey). ANOVA, *p<0.001 compared
with control.
doi:10.1371/journal.pone.0117302.g003
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Figure 4. TGF-β andmyostatin expression. (a) Cultured myoblasts incubated with DMEM and supplemented with decorin 10 ng/ml, decorin 25 ng/ml, 10%
PRP exudate and 20% PRP exudate (ELISA). Cytokine expression was measured after 48 hours of incubation. (b): TGF-β expression. (c): MSTN
expression. Three independent tests were performed and the results were expressed by the absolute absorbance values (in grey) and mean ratios (%, ± SD)
of absorbance in treated wells to those in control wells (in blue). ANOVA, p<0.001 compared with control, *p<0.005 compared with decorin. In PRP group,
no cells were growing in the well in order to determine the TGF-β content in PRP.
doi:10.1371/journal.pone.0117302.g004
Figure 5. TGF-β and MSTN expression (ELISA). Three independent tests were performed for each
cytokine and the results are expressed by the mean ratios (%) of absorbance in treated wells to those in
control wells. ANOVA, p<0.001 compared to control.
doi:10.1371/journal.pone.0117302.g005
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5,000 cells of each population positive for CD56. Further cells were hierarchically gated accord-
ing to co-expression of CD56 and MyoD and/or myogenin as markers of early and late stages
of differentiation (Fig. 6).
In the PRP-treated group 39.1% more myogenin positive cells were detected compared to
the control. Moreover, there was a 3.09% increase in cells positive only for myogenin, whereas
no such cells were found in the control cell population. The population of cells positive only
for myogenin is considered as fully differentiated and capable of fusion into myotubes as well
as future mucle fibers and is thus of great importance for muscle regeneration. At the same
time 20.6% fewer cells remained quiescent (positive only for CD56). Cells positive for both
MyoD and myogenin represent the population that shifted significantly towards mature myo-
cites during myogenesis but are not yet fully committed.
While decorin alone led only to a slightly increased differential shift when compared to
PRP, it was shown to exert a synergistic effect with PRP. The combination led to a 16.7%
Figure 6. Myogenic differentiation of hMC. Each sample consisted of 5,000 cells that were hierarchically gated according to the expression of specific
markers (top right). Top left: Aspect ratio versus cell area gated on a bivariate plot in order to isolate single cells; middle left: subgroup of previously gated
cells in focal plane positive with CD56 surface marker selected using a two-dimensional plot of image contrast versus root-mean-squared (rms) gradient;
bottom left: presence of MyoD and/or myogenin exclusively in CD56 positive cells by measuring the intensity of each probe. Bottom right: Results are
expressed as percentage ratios between cells positive only for CD56, those additionally positive for MyoD and those expressing also myogenin or myogenin
alone in each treated as well as each untreated population of cells. Scale bar = 50 μm.
doi:10.1371/journal.pone.0117302.g006
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increase in cells positive for both myogenin and MyoD (compared to PRP alone). When com-
pared to the control, the combination led to a 60.4% increase in cells positive for myogenin and
MyoD and a 46.2% decrease among quiescent cells (only CD56+).
In order to visualize the cultured cells and study the presence of desmin-containing myo-
cites we took photomicrographs using a confocal laser microscope. We stained the nuclei,
α-tubulin, to visualize the cell cytoplasm, and desmin, an intermediate filament as one of the
key markers of myogenic differentiation of myoblasts [39,40]. A color selection tool and histo-
gram analysis were performed using Adobe Photoshop to count the pixels as desmin positive
(Fig. 7). A statistically significant up-regulation of desmin expression (p<0.01 for the PRP
treated group, p<0.005 for the decorin and PRP + decorin treated groups) was present in all
therapeutic groups when compared to the control. While no significant difference was found
between the PRP and decorin-treated groups, their combination led to a more than 3-fold in-
crease (p<0.005) of desmin expression when compared to single bioactives.
Discussion
Despite the limited number of relevant reports confirming its value, platelet-rich plasma (PRP) as
a source of autologous growth factors is widely used in therapy of tendinopathies and ligament in-
juries. Recently, increasing tendencies [41,42] to use PRP to improve skeletal muscle regeneration
after injury, raise concerns especially because of one PRPs specific growth factor TGF-β, which is
known to impair the process of muscle regeneration. However, our study suggests the opposite.
By improving the metabolic activity of myoblasts, we not only excluded the potential cytostatic ef-
fect of PRP, but also showed its positive effect on the viability as well as the proliferation of hMC.
These findings correlate well with a few previous publications about the positive effects of PRP
Figure 7. Desmin expressingmyotubules. Immunofluorescence staining for merged stained nuclei (blue),
α-tubulin (red), and desmin (green). Three independent tests were performed and the results are expressed
by the mean values of “Selective color” pixel count (in grey) and mean ratios (%, ± SD) of pixel count in the
treated group to those in control groups (in blue). ANOVA, * p<0.01, ** p<0.005 compared with the control.
(a) control, (b) decorin-treated group, (c) PRP-treated group, (d) PRP and decorin-treated group. Evident
differences can be seen in the polynucleated myotubules count and in desmin expression among the control
and PRP and/or decorin treated groups. Scale bar = 200 μm.
doi:10.1371/journal.pone.0117302.g007
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and various individual growth factors on skeletal muscle regeneration [9,10,11,12,30,43]. The in-
hibitory effects on TGF-β caused by PRP were also significantly higher when compared to dec-
orin, which was identified as a powerful regulatory agent of muscle regeneration [17,19,20,26].
Although PRP represents a significant source of TGF-β, its overall expression in hMC was
down-regulated and was surprisingly greater when compared to hMC treated with decorin,
which is one of the most potent TGF-β antagonists [44]. The mechanism behind such an effect re-
mains unknown. It seems as though there is a synergistic connection between multiple PRP-
derived growth factors responsible for the outcome and this will be the focus of our future studies.
MSTN is produced rather by skeletal muscle cells and is normally not present in autologous
platelet concentrates. Although MSTN does circulate in the blood and may therefore theoreti-
cally appear in the preparation no concerns about MSTN-induced fibrotic remodelling after in-
tramuscular PRP injection are found in the literature. However, our data shows that MSTN
expression by hMC was down-regulated when treated with PRP in comparison to non-treated
cells and almost reached the regulatory level of decorin which is believed to be one of the stron-
gest inhibitors of MSTN activity.
PRP itself down-regulates TGF-β expression in hMC and further reduction is possible with
additional inhibition of TGF-β by decorin. After co-cultivation of hMC with PRP and decorin,
a 60% decrease in TGF-β expression was identified indicating their synergistic effect.
During muscle regeneration satellite cell progenitors are being activated from the quiescent
state followed by the expression of MRFs, while some of the satellite cells remain inactive to pro-
vide a further regenerative scaffold. The whole process is mediated by TGF-β and MSTN [45,46]
[47,48,49]. Advanced single-cell analysis showed a significant increase of cells expressing MyoD
and/or myogenin, which are both MRFs characteristic for myogenic differentiation. Again, syn-
ergism of PRP and decorin is evident as the combination of both leads not only to a duplicated
count of active satellite cells, but also to a significant shift in myogenic terminal differentiation.
We also showed an evident increase in desmin expression, as well as polynuclear cell count
after PRP and decorin treatment. Desmin is a muscle-specific intermediate filament protein ex-
pressed early and late in the myogenic program and accumulated during myogenesis In vitro
[50]. Its expression is directly controlled by MyoD and myogenin and is, as the first expressed
cytoskeletal protein during myogenesis, one of the key markers of muscle commitment [51,52].
Our findings correlate with the up-regulation of MyoD and myogenin activation detected
using imaging flow cytometry, and serve as additional proof of myogenic shifts towards termi-
nal myoblast differentiation.
Conclusion
Activation of satellite cells and myogenic differentiation of proliferating myoblasts are two crucial
steps for effective skeletal muscle regeneration. Our findings suggest that preparations of autolo-
gous growth factors might act as a relevant therapeutic option for skeletal muscle injuries, despite
the fact that they represent an additional source of TGF-β. In combination with TGF-β antago-
nist decorin, the effect of this cytokine can be eliminated. This study presents not only new
mechanistic insights into the effects of PRP, but also a possible new therapeutic approach for in-
jured skeletal muscle. Although human studies are due to take place in order to confirm the In
vivo value of our findings, it seems that decorin-supplemented PRP therapy can be rationalized.
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